Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
Earnings Data
Report Date
Aug 14, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.42Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 16.29%
|Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by MDxHealth, with consistent revenue growth driven by tissue-based tests and improved gross margins. However, challenges remain with increased net loss and the impact of a significant earn-out payment. Overall, the company's strategic positioning and future outlook appear positive, but financial losses present ongoing challenges.Company Guidance
During the MDxHealth First Quarter 2025 Earnings Conference Call, the company reaffirmed its financial guidance, projecting revenue between $108 million to $110 million for the fiscal year of 2025, aligning with their objective of 20% revenue growth. The call highlighted a 22% increase in Q1 revenue to $24.3 million and a 41% growth in tissue-based test volumes. Total billable volumes reached approximately 24,000 tests, up 24% from the previous year. The company emphasized its strong market position in precision diagnostics for prostate cancer, driven by successful integration and adoption of their Confirm mdx and GPS tests, which accounted for 85% of Q1 revenue. MDxHealth also reported a gross margin increase to 63.8% and expected to achieve positive adjusted EBITDA in Q2 2025, showcasing operational discipline and sustained growth across their urology diagnostic offerings.Consistent Revenue Growth
Achieved 16th consecutive quarter of 20% or greater revenue growth, with Q1 2025 revenue growth at 22%.
Strong Tissue-Based Test Performance
Tissue-based test volume grew 41% for the quarter, indicating significant market penetration and acceptance.
Improved Gross Profit and Margin
Gross profit increased 29% to $15.5 million, with gross margins rising to 63.8% from 60.8% in Q1 2024.
Positive Adjusted EBITDA Trend
Adjusted EBITDA improved by 71% to negative $1.3 million, with expectations to achieve positive adjusted EBITDA in Q2 2025.
Strategic Positioning in Prostate Cancer Diagnostics
MDxHealth positioned as a leader with proprietary tests like Confirm and GPS, capturing a significant portion of a $500 million market opportunity.
MDXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.78 | $1.90 | +6.74% |
Feb 26, 2025 | $1.83 | $1.86 | +1.64% |
Nov 06, 2024 | $2.08 | $2.09 | +0.48% |
Aug 21, 2024 | $3.27 | $2.87 | -12.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MDxHealth (MDXH) report earnings?
MDxHealth (MDXH) is schdueled to report earning on Aug 14, 2025, TBA Not Confirmed.
What is MDxHealth (MDXH) earnings time?
MDxHealth (MDXH) earnings time is at Aug 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXH EPS forecast?
MDXH EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.